ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · IEX Real-Time Price · USD
63.25
+1.22 (1.97%)
Jul 26, 2024, 4:00 PM EDT - Market closed
ANI Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year Ending | TTM | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | 2018 - 2013 |
|---|---|---|---|---|---|---|---|
| Revenue | 517.46 | 486.82 | 316.39 | 216.14 | 208.48 | 206.55 | Upgrade
|
| Revenue Growth (YoY) | 44.26% | 53.87% | 46.38% | 3.67% | 0.93% | 2.47% | Upgrade
|
| Cost of Revenue | 192.96 | 181.51 | 133.49 | 100.61 | 87.16 | 63.15 | Upgrade
|
| Gross Profit | 324.5 | 305.3 | 182.9 | 115.53 | 121.32 | 143.39 | Upgrade
|
| Selling, General & Admin | 173.25 | 161.7 | 114.64 | 84.29 | 64.99 | 55.84 | Upgrade
|
| Research & Development | 38.87 | 34.29 | 22.32 | 11.37 | 16 | 19.81 | Upgrade
|
| Depreciation & Amortization | 59.78 | 59.79 | 56.97 | 47.25 | 44.64 | 44.61 | Upgrade
|
| Other Operating Expenses | - | - | - | 0.78 | 11.26 | 6.71 | Upgrade
|
| Operating Expenses | 271.9 | 255.77 | 193.93 | 143.7 | 136.89 | 126.97 | Upgrade
|
| Operating Income | 52.6 | 49.53 | -11.03 | -28.17 | -15.57 | 16.43 | Upgrade
|
| Interest Expense | -34.54 | -35.07 | -30.72 | -11.95 | -9.48 | -13.47 | Upgrade
|
| Interest & Investment Income | 10.7 | 8.13 | 2.67 | 0.02 | 0.03 | 0.5 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.16 | -0.16 | -0.08 | -4.71 | -0.49 | -0.23 | Upgrade
|
| EBT Excluding Unusual Items | 28.6 | 22.43 | -39.17 | -44.8 | -25.52 | 3.23 | Upgrade
|
| Merger & Restructuring Charges | -0 | -1.13 | -15.08 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 9.66 | - | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 5.35 | - | 0.75 | 1.82 | - | - | Upgrade
|
| Asset Writedown | - | - | -0.11 | -2.37 | -0.45 | -0.08 | Upgrade
|
| Legal Settlements | - | - | - | -8.75 | - | - | Upgrade
|
| Other Unusual Items | -0.56 | -1.43 | -9.06 | -1.96 | - | - | Upgrade
|
| Pretax Income | 43.04 | 19.87 | -62.67 | -56.06 | -25.96 | 3.16 | Upgrade
|
| Income Tax Expense | 7.5 | 1.09 | -14.77 | -13.46 | -3.41 | -2.94 | Upgrade
|
| Earnings From Continuing Operations | 35.55 | 18.78 | -47.9 | -42.6 | -22.55 | 6.09 | Upgrade
|
| Net Income | 35.55 | 18.78 | -47.9 | -42.6 | -22.55 | 6.09 | Upgrade
|
| Preferred Dividends & Other Adjustments | 5 | 3.3 | 1.63 | 0.19 | - | 0.1 | Upgrade
|
| Net Income to Common | 30.55 | 15.48 | -49.52 | -42.79 | -22.55 | 6 | Upgrade
|
| Net Income Growth | - | - | - | - | - | -60.67% | Upgrade
|
| Shares Outstanding (Basic) | 19 | 18 | 16 | 13 | 12 | 12 | Upgrade
|
| Shares Outstanding (Diluted) | 19 | 18 | 16 | 13 | 12 | 12 | Upgrade
|
| Shares Change (YoY) | 15.88% | 11.89% | 29.09% | 5.28% | -0.63% | 2.28% | Upgrade
|
| EPS (Basic) | 1.64 | 0.86 | -3.05 | -3.40 | -1.88 | 0.51 | Upgrade
|
| EPS (Diluted) | 1.62 | 0.85 | -3.05 | -3.40 | -1.88 | 0.50 | Upgrade
|
| EPS Growth | - | - | - | - | - | -61.54% | Upgrade
|
| Free Cash Flow | 104.7 | 110.09 | -40.08 | 0.77 | 9.13 | 39 | Upgrade
|
| Free Cash Flow Per Share | 5.53 | 6.05 | -2.46 | 0.06 | 0.76 | 3.24 | Upgrade
|
| Gross Margin | 62.71% | 62.71% | 57.81% | 53.45% | 58.19% | 69.42% | Upgrade
|
| Operating Margin | 10.16% | 10.17% | -3.49% | -13.03% | -7.47% | 7.95% | Upgrade
|
| Profit Margin | 6.87% | 3.86% | -15.14% | -19.71% | -10.82% | 2.95% | Upgrade
|
| Free Cash Flow Margin | 20.23% | 22.61% | -12.67% | 0.35% | 4.38% | 18.88% | Upgrade
|
| EBITDA | 112.38 | 109.32 | 48.62 | 19.08 | 29.07 | 61.04 | Upgrade
|
| EBITDA Margin | 21.72% | 22.46% | 15.37% | 8.83% | 13.94% | 29.55% | Upgrade
|
| D&A For EBITDA | 59.78 | 59.79 | 59.65 | 47.25 | 44.64 | 44.61 | Upgrade
|
| EBIT | 52.6 | 49.53 | -11.03 | -28.17 | -15.57 | 16.43 | Upgrade
|
| EBIT Margin | 10.16% | 10.17% | -3.49% | -13.03% | -7.47% | 7.95% | Upgrade
|
| Effective Tax Rate | 17.41% | 5.50% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template.